Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. (2017)
Attributed to:
CANCER: Trials with potential global reach and other challenging trials
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(17)30043-8
PubMed Identifier: 28163000
Publication URI: http://europepmc.org/abstract/MED/28163000
Type: Journal Article/Review
Volume: 18
Parent Publication: The Lancet. Oncology
Issue: 3
ISSN: 1470-2045